Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Macular Diseases

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study

JAMA Ophthalmol.

Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group

doi: 10.1001/jamaophthalmol.

COMMENTED

Macular Diseases

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

JAMA Ophthalmol.

Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.

doi: 10.1001/

Macular DiseasesRetinal Diseases

A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

Acta Ophthalmol.

Spooner K Hong T, Bahrami B, Chang A

doi: 10.1111/aos.13802.

Macular DiseasesRetinal Diseases

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial

Ophthalmol Retina.

Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) Study Group.

doi: 10.1016/j.oret.2019.12.019.

COMMENTED

Macular DiseasesRetinal Diseases

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion

J Ophthalmol.

Nghiem-Buffet S, Glacet-Bernard A, Addou-Regnard M, Souied EH, Cohen SY, Giocanti-Auregan A

doi: 10.1155/2018/8656495.

ConjunctivitisFlammer SyndromeMacular DiseasesRetinal DiseasesCataracts

12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

Acta Ophthalmol

Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, Guillemin M, Fraser-Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D

doi: 10.1111/aos.15014

Macular DiseasesRetinal DiseasesFurther Publications

Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol

Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.

doi: 10.1001/jamaophthalmol.2021.4395

Retinal Diseases

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion

JAMA Ophthalmol.

Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP

doi: 10.1001/jamaophthalmol.

Macular Diseases

Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

Br J Ophthalmol

Hunt AR, Nguyen V, Creuzot-Garcher CP, Alforja S, Gabrielle PH, Zarranz-Ventura J, Guillemin M, Fraser-Bell S, Casaroli Marano RP, Arnold J, McAllister IL, O'Toole L, Gillies MC, Barthelmes D, Mehta H

doi: 10.1136/bjophthalmol-2020-318491

Related content

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion

12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion

Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry